Business of Cannabis | Europe’s Post

💡Day 1 of the Indian Society for Clinical Research Research, in collaboration with the FDA, Workshop on "Conduct Matters: Regulatory Perspectives in the Design and Execution of BA/BE Studies for Generic Drugs" has successfully wrapped up! ZENOVEL team had a great time engaging with industry experts, and sharing insights into the evolving regulatory landscape for BA/BE studies. Stay tuned for more updates as we continue our journey through the conference!💼✨ #GenericDrugs #RegulatoryCompliance #Bioequivalence #BA #BE #Zenovel

It was a pleasure attending Day 1 of the ISCR conference, where we had insightful discussions on BA/BE studies and regulatory compliance for generic drugs. Proud to contribute to the future of clinical research and be part of the Zenovel team! #ISCR2024 #BA #BE #RegulatoryCompliance #Bioequivalence"

Berlin Agenda 📢 Medical Products and Pricing 📅 1:30-5:30pm, October 23rd, 2024 📍 Palisa, Palisadenstraße 48, 10243 Berlin The removal of restrictions on product requirements, which previously limited the competitiveness of German cannabis products, is expected to lead to significant changes in the market. German products, now free to develop without stringent constraints, could see improvements in quality and cannabinoid profiles, potentially rivaling Canadian imports. Patient demand is also shifting, with a growing preference for balanced and high-CBD products over the traditionally sought-after high-THC options. Understanding these evolving product trends will be crucial for companies aiming to stay ahead in the competitive German market. Get your tickets now 🎫 https://lnkd.in/d5xk5Dg8 #germany #berlin #telemedicine #cannabis #cannabisindustry #cannabisbusiness #events

🌍💼 The global medical cannabis market surged to USD 17.08 billion in 2023, projected to reach USD 77.13 billion by 2032 with an 18.24% CAGR. Led by America, which dominates with a 12.79% growth rate, the market benefits from increased R&D and changing legalities in Asia and Africa, opening new avenues. Europe follows closely, expected to grow at 12.81%, driven by expanding legalization and rising medical applications. Learn more about this booming industry at Straits Research. Read the Full Article ➡️ https://bit.ly/3zsXA7n #MedicalCannabis #MarketInsights #GlobalHealth #IndustryTrends

We are proud to be featured in Η ΝΑΥΤΕΜΠΟΡΙΚΗ | NAFTEMPORIKI, where our latest achievements and vision for innovation in medical cannabis are showcased. 🌍✨ Read more (in Greek) about our vision and milestones in the recent Naftemporiki feature. #CurityPharma #MedicalCannabis #Innovation #Investment #Naftemporiki #Greece

Cannabis is a wonder plant that possesses a strong healing ability. Research shows that you can cope with seizures by adding medical cannabis to your life. Cannabis is the powerhouse of many cannabinoids. learn more:https://lnkd.in/gDNshjQW

Check out this fantastic conversation between Sheri Courteau and Dr. Jackie from Green Philosophy 716, diving into the medicinal benefits of Cannabis and Pain Points in the Cannabis Industry!

I have seen much dialogue on LinkedIn as to whether rescheduling to Schdule 3 is good or bad for the industry - and if it will drive big Pharma into the space! As such, I am going to throw out a question for all of you! 1) Is it likely or even a good possibility that the medical side of the cannabis industry is likely to become more integrated with the pharmaceutical model, with increased research, tax benefits, and specialized medical-focused businesses and products; while the recreational side likely continue to be primarily served through the dispensary model, with separate regulations and tax structures? Common sense to me causes the question to be asked - how does a recreational product disappear and completely move to the medical / pharma side? I can see the possibility of a mix on the medical side just like we saw derivative drugs on the CBD side (i.e. Epidiolex). But in my opinion I am struggling with the fact that if we drive this into medical and big pharma route - how does it remain affordable? How does this drive out the illicit market? Is a combo likely? Hmmmmmm!

Is supply chain the reason of high price of Medicines in United States? US pay 10x higher prices for prescription drugs despite having 7 companies among top 10 pharma globally!!! Do you know why? There are three main drivers--- 1. No Price Regulator 2. Multiple intermediaries - Opaque Supply Chain 3. Unique Patent Monopoly - Evergreening Discover the shocking truths behind the soaring prices, from complex and opaque supply chains to prolonged patent monopolies. Swipe right to dive in! 📊💊 Share your thoughts or stories in the comments below. Let's start a conversation and raise awareness together! #supplychain #prescriptiondrugsUSA #Pharma #PBMs #HealthInsurance #HighPrice Follow Strategy Unchained and Gaurav Singh Chaudhary for more interesting business stories and in-depth case studies.

I recently had the opportunity to pre-review this comprehensive report on the German medical cannabis market, with a specific focus on cannabis flower, and I must say that it stands out for its depth and detail. This report is unmatched in its thorough examination of the market and offers valuable insights. If you're looking for the most detailed and up-to-date analysis available, this is the report to rely on.